AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15182984 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral anterior cruciate ligament deficiency
Number of subjects: 9
Study 10740139 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 234
Study 10740139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 8934356 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (10-50 mmol/day) for 12 months
Number of subjects: 54
Study 8934356 — intervention group
Group type: COMPARATOR
Intervention: Low sodium intake
Number of subjects: 54
Study 1524754 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer pre‐brush rinse (0.03% triclosan and 0.125% copolymer)
Number of subjects: 114
Study 1524754 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre‐brush rinse
Number of subjects: 114
Study 3905700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 77
Study 3905700 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 77
Study 31509331 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleselumab + IR-TAC
Number of subjects: 138
Study 31509331 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleselumab + MMF
Number of subjects: 138
Study 31509331 — intervention group
Group type: COMPARATOR
Intervention: SoC
Number of subjects: 138
Study 31151481 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cardiac monitoring with ILR implantation plus standard of care
Number of subjects: 164
Study 31151481 — intervention group
Group type: COMPARATOR
Intervention: Standard of care with annual 24 h or 5‐day Holter monitor
Number of subjects: 164
Study 28840277 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 kVp with 25 mL contrast medium (CM)
Number of subjects: 50
Study 28840277 — intervention group
Group type: COMPARATOR
Intervention: 100 kVp with 40 mL contrast medium (CM)
Number of subjects: 50
Study 26161708 — intervention group
Group type: EXPERIMENTAL
Intervention: 25000 IU/d retinyl palmitate for six months followed by 10000 IU/d retinyl palmitate for another six months
Number of subjects: 101
Study 26161708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 24012432 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (loading dose 60 mg)
Number of subjects: 70
Study 24012432 — intervention group
Group type: COMPARATOR
Intervention: TAP (loading dose aspirin 300 mg, clopidogrel 600 mg, cilostazol 200 mg)
Number of subjects: 70
Study 21992247 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcutaneous piezoelectric current (6 µA)
Number of subjects: 15
Study 21992247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no current)
Number of subjects: 15
Study 19703071 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant radiotherapy
Number of subjects: 473
Study 19703071 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant radiochemotherapy
Number of subjects: 473
Study 19703071 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 473
Study 19703071 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery alone (control group)
Number of subjects: 473
Study 17405898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin-based regimens)
Number of subjects: 0
Study 17405898 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of angiogenesis pathways and epidermal growth factor receptor
Number of subjects: 0
Study 15081328 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline dextran (HSD)
Number of subjects: 0
Study 11457747 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 506
Study 11457747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 9870344 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (30 mg p.o.)
Number of subjects: 14
Study 9870344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7986439 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond (CLB)
Number of subjects: 40
Study 7986439 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma 2000
Number of subjects: 40
Study 7986439 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose (SMP)
Number of subjects: 40
Study 7986439 — intervention group
Group type: COMPARATOR
Intervention: In vitro samples
Number of subjects: 40
Study 2537566 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (initial dose and maintenance therapy for 12 weeks)
Number of subjects: 19
Study 2537566 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (readministration after 12 weeks)
Number of subjects: 19
Study 31023931 — intervention group
Group type: EXPERIMENTAL
Intervention: Genicular nerve radiofrequency ablation (GN-RFA)
Number of subjects: 70
Study 31023931 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 70
Study 27682745 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative counseling with the use of a validated, online risk calculator for de novo SUI after POP surgery
Number of subjects: 33
Study 27682745 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative counseling
Number of subjects: 33
Study 25904733 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie cranberry juice (LCCJ)
Number of subjects: 56
Study 25904733 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 56
Study 23594572 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted multimedia patient intervention
Number of subjects: 867
Study 23594572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multimedia patient intervention
Number of subjects: 867
Study 23594572 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 867
Study 23594572 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 867
Study 21772173 — intervention group
Group type: EXPERIMENTAL
Intervention: Macropore
Number of subjects: 331
Study 21772173 — intervention group
Group type: COMPARATOR
Intervention: Medpor
Number of subjects: 331
Study 19493352 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided antibiotic therapy (discontinued if PCT <1 ng/ml or dropped to 25-35% of initial value over three days)
Number of subjects: 110
Study 19493352 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic regimen (applied over eight days)
Number of subjects: 110
Study 16786535 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylthioadenosine (MTA)
Number of subjects: 0
Study 15571523 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6-9 mg/day for 14 days)
Number of subjects: 31
Study 15571523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 15571523 — intervention group
Group type: COMPARATOR
Intervention: Melatonin and Placebo
Number of subjects: 31
Study 11091247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 51
Study 11091247 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 51
Study 9264277 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental dietary cellulose
Number of subjects: 13
Study 9264277 — intervention group
Group type: COMPARATOR
Intervention: No cellulose (control group)
Number of subjects: 13
Study 8317726 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 0.15 mg/kg bolus of mivacurium (Group I)
Number of subjects: 30
Study 8317726 — intervention group
Group type: COMPARATOR
Intervention: Two 0.075 mg/kg boluses of mivacurium separated by 60 s (Group II)
Number of subjects: 30
Study 3525714 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforated mallet finger splint
Number of subjects: 0
Study 3525714 — intervention group
Group type: COMPARATOR
Intervention: Conventional splint
Number of subjects: 0
Study 31352797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (70% fat, 25% protein, 5% carbohydrate)
Number of subjects: 0
Study 31352797 — intervention group
Group type: COMPARATOR
Intervention: American Cancer Society diet (ACS; high-fiber and lower-fat)
Number of subjects: 0
Study 31352797 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD) adherence
Number of subjects: 0
Study 29856465 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity itch stimuli during nocebo learning phase
Number of subjects: 97
Study 29856465 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction or reversal of nocebo effects
Number of subjects: 97
Study 29856465 — intervention group
Group type: COMPARATOR
Intervention: Lower intensity itch stimuli during nocebo learning phase
Number of subjects: 97
Study 27690710 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300) with patient support program
Number of subjects: 3270
Study 27690710 — intervention group
Group type: COMPARATOR
Intervention: Other basal insulin with available patient support programs
Number of subjects: 3270
Study 27690710 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 3270
Study 24169027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 5 mg/day (adjustable from 2.5 to 10 mg/day based on response and tolerability)
Number of subjects: 834
Study 24169027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine treatment for 52 weeks
Number of subjects: 834
Study 22809064 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes patients with comorbid RA
Number of subjects: 256331
Study 22809064 — intervention group
Group type: COMPARATOR
Intervention: Diabetes patients without RA
Number of subjects: 256331
Study 20966393 — intervention group
Group type: EXPERIMENTAL
Intervention: New method MI (MI-N)
Number of subjects: 0
Study 20966393 — intervention group
Group type: COMPARATOR
Intervention: Classic method MI (MI-C)
Number of subjects: 0
Study 20966393 — intervention group
Group type: COMPARATOR
Intervention: Sham (S-N)
Number of subjects: 0
Study 20966393 — intervention group
Group type: COMPARATOR
Intervention: Sham (S-C)
Number of subjects: 0
Study 18843828 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention
Number of subjects: 120
Study 15741815 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol
Number of subjects: 90
Study 15741815 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 90
Study 12418566 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sevoflurane (group S)
Number of subjects: 17
Study 12418566 — intervention group
Group type: COMPARATOR
Intervention: 50% nitrous oxide in oxygen (group N)
Number of subjects: 17
Study 11759128 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 0.2 mg/kg
Number of subjects: 61
Study 11759128 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 0.4 mg/kg
Number of subjects: 61
Study 11759128 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 61
Study 9289466 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation treatment
Number of subjects: 41
Study 1830145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizer
Number of subjects: 48
Study 1830145 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizer
Number of subjects: 48
Study 1830145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine mesylate
Number of subjects: 48
Study 1830145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentamidine isethionate
Number of subjects: 48
Study 6356897 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (100 to 400 mg three times a day)
Number of subjects: 20
Study 6356897 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 to 50 mg three times a day)
Number of subjects: 20
Study 30777293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy skill acquisition (CTSA)
Number of subjects: 52
Study 30777293 — intervention group
Group type: COMPARATOR
Intervention: Control procedure focused on being exposed to theories of automatic thinking
Number of subjects: 52
Study 31279814 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir prophylaxis through 14 weeks post-transplant
Number of subjects: 0
Study 31279814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28614091 — intervention group
Group type: EXPERIMENTAL
Intervention: 40U daxibotulinumtoxinA
Number of subjects: 268
Study 28614091 — intervention group
Group type: COMPARATOR
Intervention: 20U onabotulinumtoxinA
Number of subjects: 268
Study 28614091 — intervention group
Group type: EXPERIMENTAL
Intervention: 60U daxibotulinumtoxinA
Number of subjects: 268
Study 28614091 — intervention group
Group type: COMPARATOR
Intervention: 20U daxibotulinumtoxinA
Number of subjects: 268
Study 28614091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 26190370 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check and individual lifestyle counselling (intervention group)
Number of subjects: 11629
Study 26190370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health check or lifestyle counselling)
Number of subjects: 11629
Study 23458606 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtle stereotype threat (ST) condition
Number of subjects: 294
Study 23458606 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no ST)
Number of subjects: 294
Study 21256802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (5, 6, 7, 8, or 9 hours of sleep for four consecutive nights)
Number of subjects: 88
Study 21256802 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery nights (2 nights of recovery sleep)
Number of subjects: 88
Study 21256802 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnographic monitoring
Number of subjects: 88
Study 17582406 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 0
Study 17582406 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 16790656 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol 1 g
Number of subjects: 80
Study 16790656 — intervention group
Group type: COMPARATOR
Intervention: Parecoxib 40 mg
Number of subjects: 80
Study 16790656 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1 g
Number of subjects: 80
Study 16790656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 16790656 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 12359036 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management + patch
Number of subjects: 175
Study 12359036 — intervention group
Group type: COMPARATOR
Intervention: Relapse prevention + patch
Number of subjects: 175
Study 12359036 — intervention group
Group type: COMPARATOR
Intervention: Patch-only
Number of subjects: 175
Study 12359036 — intervention group
Group type: COMPARATOR
Intervention: Relapse prevention + contingency management + patch
Number of subjects: 175
Study 12359036 — intervention group
Group type: EXPERIMENTAL
Intervention: Weeks when participants met criteria for smoking abstinence
Number of subjects: 175
Study 10092007 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FMDV Ad5-P1 vaccine
Number of subjects: 3
Study 10092007 — intervention group
Group type: COMPARATOR
Intervention: Ad5 wt vaccine
Number of subjects: 3
Study 7768584 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (40 mEq Na+/d)
Number of subjects: 22
Study 7768584 — intervention group
Group type: COMPARATOR
Intervention: High-salt diet (200 mEq Na+/d)
Number of subjects: 22
Study 2107520 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 0
Study 2107520 — intervention group
Group type: COMPARATOR
Intervention: PRP vaccine
Number of subjects: 0
Study 515188 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation with maximum resistance
Number of subjects: 50
Study 515188 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive neuromuscular facilitation patterning without resistance
Number of subjects: 50
Study 515188 — intervention group
Group type: COMPARATOR
Intervention: Weight training
Number of subjects: 50
Study 6298849 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg)
Number of subjects: 13
Study 6298849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30239829 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-based ART
Number of subjects: 150
Study 30239829 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 150
Study 29770623 — intervention group
Group type: EXPERIMENTAL
Intervention: Round loop electrode (LE group)
Number of subjects: 96
Study 29770623 — intervention group
Group type: COMPARATOR
Intervention: Punch biopsy forceps (PB group)
Number of subjects: 96
Study 29770623 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 26915026 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.4% sodium bicarbonate infusion (0.5 mEq/kg/h for the first hour; 0.15 mEq/kg/h until completion of surgery)
Number of subjects: 60
Study 26915026 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride infusion
Number of subjects: 60
Study 24953768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 122
Study 24953768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi plus CBI
Number of subjects: 122
Study 23061240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone daily for 30 days (in smokers)
Number of subjects: 0
Study 23061240 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone daily for 30 days (in nonsmokers)
Number of subjects: 0
Study 20435307 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tapes
Number of subjects: 310
Study 17275657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous valproate infusion at doses ranging from 7.5 to 41.5 mg/kg and rates of 1.5 to 11 mg/kg per minute
Number of subjects: 18
Study 16088161 — intervention group
Group type: EXPERIMENTAL
Intervention: Daivobet (calcipotriol/betamethasone dipropionate), 4 weeks followed by calcipotriol, 4 weeks
Number of subjects: 0
Study 16088161 — intervention group
Group type: COMPARATOR
Intervention: Tacalcitol, 8 weeks
Number of subjects: 0
Study 11795622 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong therapy
Number of subjects: 86
Study 11795622 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (lofexidine‐HCl)
Number of subjects: 86
Study 11795622 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 86
Study 10047929 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa (200 mg + 50 mg benserazide, PO)
Number of subjects: 22
Study 10047929 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg)
Number of subjects: 22
Study 10047929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10047929 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa (600 mg/d for 11 days)
Number of subjects: 22
Study 10047929 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg) after chronic treatment
Number of subjects: 22
Study 7726442 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 52
Study 7726442 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 52
Study 7726442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 25 mg
Number of subjects: 52
Study 7726442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg
Number of subjects: 52
Study 7726442 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 52
Study 1688066 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine injection
Number of subjects: 29
Study 1688066 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline nebulizer inhalation
Number of subjects: 29
Study 1688066 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover treatment (both groups)
Number of subjects: 29
Study 7370603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteur antivenom (20-40 ml)
Number of subjects: 14
Study 7370603 — intervention group
Group type: COMPARATOR
Intervention: Behringwerke antivenom (60-180 ml)
Number of subjects: 14
Study 31291417 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise‐citrulline (EC)
Number of subjects: 40
Study 31291417 — intervention group
Group type: COMPARATOR
Intervention: control‐placebo
Number of subjects: 40
Study 31291417 — intervention group
Group type: COMPARATOR
Intervention: control‐citrulline
Number of subjects: 40
Study 31291417 — intervention group
Group type: COMPARATOR
Intervention: exercise‐placebo
Number of subjects: 40
Study 29898717 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacity building and text messaging intervention
Number of subjects: 354
Study 27164224 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 63
Study 27164224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 24908656 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 25 mg/m² b.i.d. and TMZ 135 mg/m²/d
Number of subjects: 29
Study 21926667 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-534 (live, attenuated RSV/PIV3 chimeric virus vaccine candidate)
Number of subjects: 49
Study 21926667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 19453850 — intervention group
Group type: EXPERIMENTAL
Intervention: Putty form demineralized bone matrix (DBM)
Number of subjects: 25
Study 19453850 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate form demineralized bone matrix (DBM)
Number of subjects: 25
Study 19453850 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (control)
Number of subjects: 25
Study 17157557 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple oral explanation (SP) + Single home visit (SH)
Number of subjects: 112
Study 17157557 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple oral explanation (SP) + Repeated home visits (RH)
Number of subjects: 112
Study 17157557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and written explanation (RP) + Single home visit (SH)
Number of subjects: 112
Study 17157557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and written explanation (RP) + Repeated home visits (RH)
Number of subjects: 112
Study 15901122 — intervention group
Group type: EXPERIMENTAL
Intervention: Protonics system with conventional exercise-based rehabilitation
Number of subjects: 34